MedTrace Logo

Clinical Efficacy of Novel Jasminum-based Calcium Hydroxide Medicament

NCT06653608 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-10-30

No results posted yet for this study

Summary

A triple-blind, parallel group, randomized trial with an allocation ratio of 1:1. Participants randomly allocated into two groups A and B. In group A, nano-reinforced calcium hydroxide medicament was utilized while in group B, calcium hydroxide medicament without nanoparticles was used. Post-operative pain was assessed after 4 hours, 24 hours, 48 hours, 72 hours, 96 hours.

Conditions

  • Necrotic Pulp
  • Acute Apical Periodontitis of Pulpal Origin

Interventions

DRUG

Nano-reinforced calcium hydroxide medicament

Group A (Calcium hydroxide intracanal medicament reinforced with jasminum derived- titania nanoparticles)

DRUG

Calcium hydroxide without nanoparicles

Group B ( Calcium hydroxide medicament without nanoparticles)

Sponsors & Collaborators

  • Pakistan Institute of Medical Sciences

    lead OTHER_GOV

Principal Investigators

  • Nehal Amir, BDS · Pakistan Institute of Medical Sciences

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-04-24
Primary Completion
2024-09-25
Completion
2024-09-25

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06653608 on ClinicalTrials.gov